Except for solid tumors, in hematologic malignancy, our previous study showed that a low RBP2 expression could not repress miR-21 expression, which promoted the transition of CML from CP to BP (16). Here, RBP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.